We are live on ! Find out more
XRTX icon

XORTX Therapeutics
XRTX

3 hedge funds and large institutions have $45K invested in XORTX Therapeutics in 2022 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

0.27% less ownership

Funds ownership: 0.53% → 0.26% (-0.27%)

40% less funds holding

Funds holding: 5 → 3 (-2)

88% less capital inflows, than outflows

Capital inflows: $10.1K | Capital outflows: $83.3K

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
3
Holders Change
-2
Holders Change %
-40%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CIBC World Market
CIBC World Market
Ontario, Canada
+$6.96K
2
UBS Group
UBS Group
Switzerland
+$3.17K

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$58K
2
Virtu Financial
Virtu Financial
New York
-$24K
3
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$1.27K

XRTX Hedge Fund Activity: Q2 2022 in Review

3 of the 5,963 institutional investors tracked by Wall St. Rank reported a position in XORTX Therapeutics (XRTX) for Q2 2022, worth a combined $45K — down 67% from $136K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of XRTX and 0 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 2 added.

The largest buyer was CIBC World Market, adding an estimated $6.96K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $58K sold.

  • 3 institutional investors held XORTX Therapeutics (XRTX) as of Q2 2022, down from 5 in Q1 2022.
  • Funds reported $45K of XORTX Therapeutics stock for Q2 2022, down 67% quarter-over-quarter.
  • 0 funds opened new XORTX Therapeutics positions in Q2 2022 and 2 closed out, a net change of -2 holders.
  • The largest XORTX Therapeutics buyer in Q2 2022 was CIBC World Market, an estimated $6.96K added.
  • The largest XORTX Therapeutics seller in Q2 2022 was Susquehanna International Group, an estimated $58K sold.

Based on aggregated 13F filings for Q2 2022.